Mononessa Alternatives Compared
| Mononessa (ethinyl estradiol / norgestimate) | Medroxyprogesterone | Norethindrone |
|
|---|
| Mononessa (ethinyl estradiol / norgestimate) | Medroxyprogesterone | Norethindrone |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Ovarian Cysts, Endometriosis, Abnormal Uterine Bleeding, Birth Control, Gonadotropin Inhibition. Mononessa may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Amenorrhea, Abnormal Uterine Bleeding, Endometrial Hyperplasia - Prophylaxis, Birth Control, Endometrial Cancer, Endometriosis, Gender Affirming Hormone Therapy , Gender Dysphoria... View more |
Prescription only
Prescribed for Abnormal Uterine Bleeding, Endometriosis, Amenorrhea, Gender Affirming Hormone Therapy , Birth Control. Norethindrone may also be used for purposes not listed in this medication guide. |
Related suggestions Birth Control
Abnormal Uterine Bleeding
Endometriosis
|
|||||||||||||||
| More about Mononessa (ethinyl estradiol / norgestimate) | More about Medroxyprogesterone | More about Norethindrone | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Mononessa has an average rating of 6.2 out of 10 from a total of 247 ratings on Drugs.com. 45% of reviewers reported a positive effect, while 27% reported a negative effect. |
Medroxyprogesterone has an average rating of 4.6 out of 10 from a total of 2469 ratings on Drugs.com. 31% of reviewers reported a positive effect, while 51% reported a negative effect. |
Norethindrone has an average rating of 4.9 out of 10 from a total of 1571 ratings on Drugs.com. 33% of reviewers reported a positive effect, while 45% reported a negative effect. |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Side Effects | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
| Lower cost generic approved |
Lower cost generic |
Lower cost generic |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Medroxyprogesterone prices |
View all Norethindrone prices |
||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||
|
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Other ethinyl estradiol / norgestimate brands include: Estarylla, Femynor, Mili, Mono-Linyah, Nymyo, Previfem, Sprintec, Tri Femynor, Tri-Estarylla, Tri-Linyah, Tri-Lo-Estarylla, Tri-Lo-Linyah, Tri-Lo-Marzia, Tri-Lo-Mili, Tri-Lo-Sprintec, Tri-Mili, Tri-Nymyo, Tri-Previfem, Tri-Sprintec, Tri-VyLibra, Tri-Vylibra Lo, VyLibra View more | Depo Provera, depo-subQ provera 104, Provera | Affodel, Camila, Deblitane, Emzahh, Errin, Gallifrey, Heather, Incassia, Jencycla, Lyleq, Lyza, Nor-QD, Norlyda, Norlyroc, Orquidea, Sharobel, Tulana View more | ||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
|
N/A |
401 hours |
10 hours |
||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 472 drugs are known to interact with Mononessa:
|
A total of 247 drugs are known to interact with Medroxyprogesterone:
|
A total of 263 drugs are known to interact with Norethindrone:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
|
||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
N/A |
June 18, 1959 |
April 21, 1982 |
||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.